Periodic Reporting for period 1 - POLYBOOST (POLYBOOST: Renovating the Polyclonal Immunotherapy)
Reporting period: 2016-12-01 to 2017-03-31
Organ transplant is the choice treatment when an organ reaches irreversible failure. More than 120,000 transplants are done worldwide every year. Unfortunately, acute and chronic rejection of the allograft irreversibly happens when an organ is transplanted between non-identical individuals, and it remains the most important cause for organ transplant failure. To diminish the graft rejection, clinicians make use of immunosuppressant drugs that are usually animal-derived products extremely toxic that trigger a wide array of side effects due to their high immunogenicity. Unfortunately, there are not safer alternatives at the market.
Our consortium has developed a unique and safer alternative to immunosuppressants. Xenothera and Avantea have developed the platform POLYBOOST, which aims to produce customized polyclonal serums with low immunogenicity. Our first product, LIS1, consists of a polyclonal serum of very low immunogenicity against human T-lymphocytes to be used as immunosuppressant during organ transplantation. According to our financial forecast we will launch LIS1 at the market by 2023.
Our most important clients and users will be the hospitals and transplant centers, clinicians and patients. Hospitals and clinicians will buy our product LIS1 because of its safety and efficacy, friendly-use, and short and long-term decrease of the total transplant cost. Patients will be the most important beneficiaries of our product, because treatment with LIS1 will decrease hazardous side effects described by other immunosuppressant serums, increase prognosis of the transplant with longer life of the graft, and in general terms, LIS1 will significantly increase the quality of life of transplanted patients.
Our consortium has developed a unique and safer alternative to immunosuppressants. Xenothera and Avantea have developed the platform POLYBOOST, which aims to produce customized polyclonal serums with low immunogenicity. Our first product, LIS1, consists of a polyclonal serum of very low immunogenicity against human T-lymphocytes to be used as immunosuppressant during organ transplantation. According to our financial forecast we will launch LIS1 at the market by 2023.
Our most important clients and users will be the hospitals and transplant centers, clinicians and patients. Hospitals and clinicians will buy our product LIS1 because of its safety and efficacy, friendly-use, and short and long-term decrease of the total transplant cost. Patients will be the most important beneficiaries of our product, because treatment with LIS1 will decrease hazardous side effects described by other immunosuppressant serums, increase prognosis of the transplant with longer life of the graft, and in general terms, LIS1 will significantly increase the quality of life of transplanted patients.
During these 4 months, we carried out a feasibility report to check the technical, commercial and financial potential of POLYBOOST. Technically, we outline the next steps of the work plan for phase 2, including the design of preclinical and clinical trial studies, and up-scaling of the DKO animals and purification of the serum for industrialization. Commercially, we carried out a detailed market analysis of immunosuppressant drugs for organ transplantation, and a patent landscape search to update our IP and confirm our freedom to operate.
Financially, we updated our sales strategy and a 5-years financial forecast, showing the profitability of our product, which will generate €300M of cumulative revenues with a ROI of 9.